Option Care Health Inc (NASDAQ: OPCH) saw its stock soar 5.08% during Wednesday's intraday trading session, following a notable upgrade from UBS and the release of impressive first-quarter 2025 financial results.
UBS raised its rating on Option Care Health from Neutral to Buy and increased its price target from $38 to $40. This upgrade comes on the heels of the company's strong Q1 2025 earnings report, which exceeded analyst expectations. Option Care Health reported revenue of $1.33 billion, up 16% year-over-year and 6% above analyst estimates. Earnings per share came in at $0.28, surpassing analyst projections by 3.2%.
The positive sentiment was further reinforced by Barrington Research, which maintained its Outperform rating on the stock. With an average analyst rating of Buy and a mean price target of $34.67, Option Care Health appears well-positioned for future growth. The company's robust performance in the face of rising healthcare demand and its ability to exceed market expectations have clearly resonated with investors, driving the significant stock price increase observed today.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。